Pharmacodynamics of TNF-α inhibitors in psoriasis

Expert Review of Clinical Pharmacology

Volumn 4, Issue 4, 2011, Pages 515-523

  Vergou, Theognosia ^a   Moustou, Aikaterini Evangelia ^a   Sfikakis, Petros P ^b   Antoniou, Christina ^a   Stratigos, Alexander J ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

inflammation; mechanism of action; pharmacodynamic properties; psoriasis; TNF a inhibitors; tumor necrosis factor

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA;

ANKYLOSING SPONDYLITIS; APOPTOSIS; CROHN DISEASE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; NONHUMAN; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; T CELL DEPLETION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79960387059     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/ecp.11.28     Document Type: Review

References (50)

1. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J. Am. Acad. Dermatol. 46(1), 1-23 (2002). (Pubitemid 34073472)
2. Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-g, interleukin-2, and tumor necrosis factor-a, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J. Invest. Dermatol. 113(5), 752-759 (1999).
3. Ferenczi K, Burack L, Pope M, Krueger JG, Austin LM. CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: blood and skin comparisons by flow cytometry. J. Autoimmun. 14(1), 63-78 (2000). (Pubitemid 30080539)
4. Ovigne JM, Baker BS, Brown DW, Powles AV, Fry L. Epidermal CD8+ T cells in chronic plaque psoriasis are Tc1 cells producing heterogeneous levels of interferon-g. Exp. Dermatol. 10(3), 168-174 (2001). (Pubitemid 32492479)
5. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther. 117(2), 244-279 (2008).
6. Smookler DS, Mohammed FF, Kassiri Z, Duncan GS, Mak TW, Khokha R. Cutting edge: tissue inhibitor of metalloproteinase 3 regulates TNF-dependent systemic inflammation. J. Immunol. 176(2), 721-725 (2006).
7. Chan FK, Chun HJ, Zheng L, Siegel RM, Bui KL, Lenardo MJ. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 288(5475), 2351-2354 (2000). (Pubitemid 30448156)
8. Grell M, Douni E, Wajant H et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83(5), 793-802 (1995).
9. Grell M, Wajant H, Zimmermann G, Scheurich P. The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc. Natl Acad. Sci. USA 95(2), 570-575 (1998). (Pubitemid 28083784)
10. Hehlgans T, Mannel DN. The TNF-TNF receptor system. Biol. Chem. 383(10), 1581-1585 (2002). (Pubitemid 35282977)
11. Seitz C, Muller P, Krieg RC, Mannel DN, Hehlgans T. A novel p75TNF receptor isoform mediating NFkB activation. J. Biol. Chem. 276(22), 19390-19395 (2001).
12. Hehlgans T, Pfeffer K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 115(1), 1-20 (2005). (Pubitemid 40598088)
13. Schottelius AJ, Moldawer LL, Dinarello CA, Asadullah K, Sterry W, Edwards CK 3rd. Biology of tumor necrosis factor-a -implications for psoriasis. Exp. Dermatol. 13(4), 193-222 (2004). (Pubitemid 38618076)
14. Nickoloff BJ, Karabin GD, Barker JN et al. Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-a in psoriasis. Am. J. Pathol. 138(1), 129-140 (1991).
15. Barnes PJ, Karin M. Nuclear factor-kB -a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 336(15), 1066-1072 (1997).
16. Gottlieb AB, Masud S, Ramamurthi R et al. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-a monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J. Am. Acad. Dermatol. 48(1), 68-75 (2003). (Pubitemid 36091536)
17. Norris DA. Cytokine modulation of adhesion molecules in the regulation of immunologic cytotoxicity of epidermal targets. J. Invest. Dermatol. 95(Suppl. 6), 111-120 (1990).
18. Simonetti O, Lucarini G, Campanati A et al. VEGF, survivin and NOS overexpression in psoriatic skin: critical role of nitric oxide synthases. J. Dermatol. Sci. 54, 205-218 (2009).
19. Vergou T, Lima XT, Kimball AB. Targeting the IL12/IL-23 cytokine family in the treatment of psoriatic disease. Exp. Rev. Dermatol. 3(4), 453-463 (2008).
20. Torti DC, Feldman SR. Interleukin-12, interleukin-23 and psoriasis. J. Am. Acad. Dermatol. 57, 1059-1068 (2007).
21. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356(9227), 385-390 (2000). (Pubitemid 30487495)
22. Scallon B, Cai A, Solowski N et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J. Pharmacol. Exp. Ther. 301(2), 418-426 (2002). (Pubitemid 34429950)
23. Scallon BJ, Trinh H, Nedelman M, Brennan FM, Feldmann M, Ghrayeb J. Functional comparisons of different tumour necrosis factor receptor/IgG fusion proteins. Cytokine 7(8), 759-770 (1995).
24. Gottlieb AB, Chamian F, Masud S et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J. Immunol. 175(4), 2721-2729 (2005). (Pubitemid 41113889)
25. Zaba LC, Cardinale I, Gilleaudeau P et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J. Exp. Med. 204(13), 3183-3194 (2007).
26. Lizzul PF, Aphale A, Malaviya R et al. Differential expression of phosphorylated NF-kB/RelA in normal and psoriatic epidermis and downregulation of NF-kB in response to treatment with etanercept. J. Invest. Dermatol. 124(6), 1275-1283 (2005). (Pubitemid 40847416)
27. Malaviya R, Sun Y, Tan JK et al. Etanercept induces apoptosis of dermal dendritic cells in psoriatic plaques of responding patients. J. Am. Acad. Dermatol. 55(4), 590-597 (2006). (Pubitemid 44436644)
28. Knight DM, Trinh H, Le J et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol. Immunol. 30(16), 1443-1453 (1993).
29. Kohno T, Tam LT, Stevens SR, Louie JS. Binding characteristics of tumor necrosis factor receptor-Fc fusion proteins vs anti-tumor necrosis factor mAbs. J. Invest. Dermatol. Symp. Proc. 12(1), 5-8 (2007). (Pubitemid 46763031)
30. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 357(9271), 1842-1847 (2001). (Pubitemid 32539117)
31. Reich K, Nestle FO, Papp K et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a Phase III, multicentre, double-blind trial. Lancet 366(9494), 1367-1374 (2005). (Pubitemid 41443403)
32. Smith CH, Jackson K, Bashir SJ et al. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study. Br. J. Dermatol. 155(1), 160-169 (2006). (Pubitemid 43876410)
33. Leigh IM, Navsaria H, Purkis PE, McKay IA, Bowden PE, Riddle PN. Keratins (K16 and K17) as markers of keratinocyte hyperproliferation in psoriasis in vivo and in vitro. Br. J. Dermatol. 133(4), 501-511 (1995).
34. Goedkoop AY, Kraan MC, Teunissen MB et al. Early effects of tumour necrosis factor a blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Ann. Rheum. Dis. 63(7), 769-773 (2004). (Pubitemid 38850446)
35. Krüger-Krasagakis S, Galanopoulos VK, Giannikaki L, Stefanidou M, Tosca AD. Programmed cell death of keratinocytes in infliximab-treated plaque-type psoriasis. Br. J. Dermatol. 154(3), 460-466 (2006). (Pubitemid 43382653)
36. Bedini C, Nasorri F, Girolomoni G, Pità O, Cavani A. Antitumour necrosis factor-a chimeric antibody (infliximab) inhibits activation of skin-homing CD4+ and CD8+ T lymphocytes and impairs dendritic cell function. Br. J. Dermatol. 157(2), 249-258 (2007). (Pubitemid 47083831)
37. Kohno T, Tam L, Ting T, Bass RB, Stevens SR. Adalimumab and infliximab bind to Fc-receptor and C1q and generate immunoprecipitation: a different mechanism from etanercept. Arthritis Rheum. 52(9), S562-S563 (2005).
38. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-a monoclonal antibody cA2 binds recombinant transmembrane TNF-a and activates immune effector functions. Cytokine 7(3), 251-259 (1995).
39. Schmitt J, Wozel G. Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature. Biologics 3, 303-318 (2009).
40. Santora LC, Kaymakcalan Z, Sakorafas P, Krull IS, Grant K. Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange, size exclusion chromatography, and BIAcore. Anal. Biochem. 299(2), 119-129 (2001). (Pubitemid 34053400)
41. Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr. Dir. Autoimmun. 11, 180-210 (2010).
42. Haider AS, Cardinale IR, Whynot JA, Krueger JG. Effects of etanercept are distinct from infliximab in modulating proinflammatory genes in activated human leukocytes. J. Invest. Dermatol. Symp. Proc. 12 (1), 9-15 (2007). (Pubitemid 46763029)
43. Kohno T, Louie JS, Stevens SR. Differences in Fc receptor and C1q binding in tumor necrosis factor (TNF) antagonists may contribute to differences in mechanisms of action. J. Invest. Dermatol. 124(4), A111 (2005).
44. Kaymakcalan Z, Sakorafas P, Bose S et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin. Immunol. 131(2), 308-316 (2009).
45. Antoniou C, Moustou AE, Vergou T, Stratigos A, Kalambokas A, Katsambas AD. Autoimmunity by anti-tumour necrosis factor-a agents: the role of traditional therapies. J. Eur. Acad. Dermatol. Venereol. 24(3), 356-357 (2010).
46. Ramos-Casals M, Brito-Zerón P, Mun̄oz S et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine 86(4), 242-251 (2007). (Pubitemid 47067483)
47. Elezoglou A, Kafasi N, Kaklamanis PH et al. Infliximab treatment-induced formation of antibodies is common in Behcet's disease. Clin. Exp. Rheumatol. 25(4 Suppl. 45), S65-S69 (2007).
48. Moustou AE, Matekovits A, Dessinioti C, Antoniou C, Sfikakis PP, Stratigos AJ. Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review. J. Am. Acad. Dermatol. 61(3), 486-504 (2009).
49. Saliu OY, Sofer C, Stein DS, Schwander SK, Wallis RS. Tumor necrosis factor blockers: differential effects on mycobacterial immunity. J. Infect. Dis. 194(4), 486-492 (2006). (Pubitemid 44162660)
50. Furst DE, Wallis RS, Broder M, Beenhouwer DO. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin. Arthritis Rheum. 36(3), 159-167 (2006). (Pubitemid 44691882)